SCHEMBL7024969

SCHEMBL7024969

CN(CCOc1ccc(N)cc1)CCc1ccc(N)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.73
HRH3 Q9Y5N1 3/20 0.62
CACNA1F O60840 1/20 0.59
CHRM2 P08172 1/20 0.59
ACHE P22303 1/20 0.59
AGTR1 P30556 1/20 0.59
DRD3 P35462 1/20 0.59
CACNA1D Q01668 1/20 0.59
CACNA1S Q13698 1/20 0.59
CACNA1C Q13936 1/20 0.59
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
TDP1 Q9NUW8 2/20 0.46
TSHR P16473 2/20 0.45
LTA4H P09960 1/20 0.45
AOC3 Q16853 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8790478 0.94 KCNH2 (0.76) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL2022333 0.89 KCNH2 (0.56) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL9628264 0.88 KCNH2 (0.58) KCNH2HRH3CACNA1FCHRM2ACHE
Hydrochloric Acid SCHEMBL5159771 0.88 KCNH2 (0.54) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL8789232 0.86 KCNH2 (0.66) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL6575217 0.85 CYP1A2 (0.67) KCNH2AOC3
SCHEMBL9628293 0.84 KCNH2 (0.88) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL9629107 0.84 KCNH2 (0.54) KCNH2HRH3CACNA1FCHRM2ACHE
SCHEMBL9628071 0.84 KCNH2 (0.88) KCNH2HRH3CACNA1FCHRM2ACHE
Hydrochloric Acid SCHEMBL9054039 0.84 BLM (0.68) KCNH2AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115055066-B Microporous polymer particle/polymer mixed matrix membrane and preparation method and application thereof 南京工业大学 2023-07-07 CN claimed
CN-115055066-A Microporous polymer particle/polymer mixed matrix membrane and preparation method and application thereof 南京工业大学 2022-09-16 CN claimed
EP-3323500-B1 MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM NANJING UNIVERSITY OF TECHNOLOGY (CN) 2021-01-27 EP claimed
US-10799836-B2 Preparation method for triptyl polymer separation membrane NANJING TECH UNIVERSITY (CN) 2020-10-13 US claimed
US-10450267-B2 Method for preparing N-[4-(2-{[2-(4-methane sulfonamidophenoxy) ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide (dofetilide) FARMAK, A.S. (CZ) 2019-10-22 US claimed
US-20190169121-A1 METHOD FOR PREPARING N-[4-(2-{[2-(4-METHANE SULFONAMIDOPHENOXY) ETHYL](METHYL)AMINO}ETHYL)PHENYL]METHANESULFONAMIDE (DOFETILIDE) FARMAK, A.S. (CZ) 2019-06-06 US claimed
US-20180236408-A1 A PREPARATION METHOD FOR TRIPTYL POLYMER SEPARATION MEMBRANE NANJING TECH UNIVERSITY (CN) 2018-08-23 US claimed
EP-3323500-A1 MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM Nanjing Tech University (CN) 2018-05-23 EP claimed
EP-0245997-B1 N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR Pfizer Limited (GB) 1992-04-15 EP claimed
EP-0245997-A2 N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor Pfizer Limited (GB) 1987-11-19 EP claimed
CN-115055066-B Microporous polymer particle/polymer mixed matrix membrane and preparation method and application thereof 南京工业大学 2023-07-07 CN disclosed
CN-115055066-A Microporous polymer particle/polymer mixed matrix membrane and preparation method and application thereof 南京工业大学 2022-09-16 CN disclosed
CN-108164429-B Preparation method of dofetilide intermediate 四川科瑞德凯华制药有限公司 2021-07-23 CN disclosed
EP-3323500-B1 MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM NANJING UNIVERSITY OF TECHNOLOGY (CN) 2021-01-27 EP disclosed
US-10799836-B2 Preparation method for triptyl polymer separation membrane NANJING TECH UNIVERSITY (CN) 2020-10-13 US disclosed
EP-0898964-A1 Method for treating heart failure PFIZER INC. (US) 1999-03-03 EP disclosed
EP-0245997-B1 N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR Pfizer Limited (GB) 1992-04-15 EP disclosed
US-5079248-A Antifibrillatory agents; side effect reduction PFIZER INC. (US) 1992-01-07 US disclosed
US-4959366-A Anti-arrhythmic agents PFIZER INC. (US) 1990-09-25 US disclosed
EP-0245997-A2 N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor Pfizer Limited (GB) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169121-A1 METHOD FOR PREPARING N-[4-(2-{[2-(4-METHANE SULFONAMIDOPHENOXY) ETHYL](METHYL)AMINO}ETHYL)PHENYL]METHANESULFONAMIDE (DOFETILIDE) SCN4A, HCN4, METTL14 KCNH2 16/4885HRH3 2831/4885CACNA1F 20/4885
US-10450267-B2 Method for preparing N-[4-(2-{[2-(4-methane sulfonamidophenoxy) ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide (dofetilide) SCN4A, HCN4, METTL14 KCNH2 16/4885HRH3 2831/4885CACNA1F 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.